

# Material Safety data sheet

## LAMOTRIGINE TABLETS (CHEWABLE, DISPERSIBLE)

Strength: 2 mg.  
Strength: 5 mg and 25 mg

Pack Size: 90 and 100 Tablets per bottle  
Pack Size: 90,100 and 500 Tablets per bottle

Revision No.: 00

### EMERGENCY OVERVIEW

Each lamotrigine tablet (chewable, dispersible) intended for oral administration contains 2 mg or 5 mg or 25 mg of lamotrigine. and excipients generally considered to be non-toxic and non-hazardous in small quantities and under conditions of normal occupational exposure.

### Section 1. Identification of the substance

#### Identification of the product

**Product name:** Lamotrigine tablet (chewable, dispersible)  
**Formula:**  $C_9H_7N_5Cl_2$   
**Chemical Name:** 3,5-diamino-6-(2,3-dichlorophenyl)-*as*-triazine  
**Therapeutic Category** an antiepileptic drug (AED)

#### Manufacturer / supplier identification

**Company:** Cadila Healthcare Ltd. Ahmedabad, India  
**Contact for information:** Tel.: +91 79 6868100 Fax: +91 79 3750319  
**Emergency telephone No.** Tel.: +91 79 6868100

### Section 2. Composition / information on ingredients

Component	Exposure Limit	CAS No.
Lamotrigine	Not Found	84057-84-1
Aspartame	Not Found	22839-47-0
Croscarmellose sodium	Not Found	74811-65-7
Flavour black currant	Not Found	-
Magnesium stearate	Not Found	557-04-0
Mannitol	Not Found	87-78-5
Microcrystalline cellulose	Not Found	9004-34-6
Silicon dioxide	Not Found	7631-89-9
Tribasic calcium phosphate	Not Found	7758-87-4

# Material Safety data sheet

## LAMOTRIGINE TABLETS (CHEWABLE, DISPERSIBLE)

Strength: 2 mg.  
Strength: 5 mg and 25 mg

Pack Size: 90 and 100 Tablets per bottle  
Pack Size: 90,100 and 500 Tablets per bottle

Revision No.: 00

### Section 3. Health Hazards Information

<b>Dose and Administration</b>	The dose is dependent on the age, weight and adjunct therapy given to the patient. The initial dose starts from 25mg/day to the maintenance dose up to 500mg / day in the divided doses. Tablets are meant for oral administration.
<b>Adverse Effects</b>	Serious rash requiring hospitalization and discontinuation of lamotrigine, including stevens-johnson syndrome and toxic epidermal necrolysis, have occurred in association with therapy with lamotrigine. Rare deaths have been reported, but their numbers are too few to permit a precise estimate of the rate.
<b>Over Dose Effect</b>	Overdoses involving quantities up to 15 g have been reported for lamotrigine, some of which have been fatal. Overdose has resulted in ataxia, nystagmus, increased seizures, decreased level of consciousness, coma, and intraventricular conduction delay.
<b>Contraindications</b>	Lamotrigine tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. The risk of serious rashes requiring hospitalization and discontinuation of lamotrigine.
<b>Pregnancy Comments</b>	No evidence of teratogenicity was found in mice, rats, or rabbits when lamotrigine was orally administered to pregnant animals during the period of organogenesis at doses up to 1.2, 0.5, and 1.1 times, respectively, on a mg/m <sup>2</sup> basis, the highest usual human maintenance dose (i.e., 500 mg/day). However, maternal toxicity and secondary fetal toxicity producing reduced fetal weight and/or delayed ossification were seen in mice and rats, but not in rabbits at these doses.
<b>Pregnancy Category</b>	C

### Section 4. First aid measures

<b>General</b>	Remove from exposure. Remove contaminated Clothing. Person developing serious hypersensitivity reaction must receive medical attention.
<b>Overdose Treatment</b>	There are no specific antidotes for lamotrigine. Following a suspected overdose, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, emesis should be induced or gastric lavage should be performed; usual precautions should be taken to protect the airway. It should be kept in mind that lamotrigine is rapidly absorbed. It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood. In 6 renal failure patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis during a 4-hour session. A Poison Control Center should be contacted for information on the management of overdosage of lamotrigine.

# Material Safety data sheet

## LAMOTRIGINE TABLETS (CHEWABLE, DISPERSIBLE)

Strength: 2 mg.  
Strength: 5 mg and 25 mg

Pack Size: 90 and 100 Tablets per bottle  
Pack Size: 90,100 and 500 Tablets per bottle

Revision No.: 00

### Section 5. Fire – fighting measures

<b>Flash point</b>	Not Found	<b>Upper Flammable Limit:</b>	Not Found
<b>Auto-Ignition Temperature:</b>	Not Found	<b>Lower Flammable Limit:</b>	Not Found
<b>Extinguishing Media</b>	Water Spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and material.	<b>Fire and Explosion Hazard</b>	This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with the dry material to dissipate the potential build up of static electricity.
<b>Fire Fighting Procedure</b>	As with all fires, evacuate personnel to a safe area. Fire fighter should use self- contained breathing equipment and protective clothing.		

### Section 6. Storage / Spill / Disposal Measures

Storage	Store at 20° to 25°C (68° to 77°F) in a dry place. Protect from light.
Spill Response	Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.
Disposal	Dispose the waste in accordance with all applicable Federal, State and local laws.

### Section 7. Exposure controls and personal protection

Respiratory Protection	Protection from inhalation is not normally necessary. If ventilation is inadequate or dust is likely to generate, use of suitable dust mask would be appropriate.
Skin Protection	Skin protection is not normally necessary, however it is good practice to avoid contact with chemical to use suitable gloves when handling.
Eye protection	Eye protection is not normally necessary. If concerned wear protective goggles or glasses. Wash hands prior to touching eye and in particular handling contact lenses.
Protective Clothing	Protective clothing is not normally necessary, however it is good practice to use apron.

# Material Safety data sheet

## LAMOTRIGINE TABLETS (CHEWABLE, DISPERSIBLE)

Strength: 2 mg.  
Strength: 5 mg and 25 mg

Pack Size: 90 and 100 Tablets per bottle  
Pack Size: 90,100 and 500 Tablets per bottle

Revision No.: 00

### Section 8. Physical and chemical properties

<b>Appearance</b>	Lamotrigine Tablets (Chewable, Dispersible), 2 mg are white to off-white, round, flat- faced, radial-edged tablets debossed with "Z" and "15" on one side and plain on the other side.  Lamotrigine Tablets (Chewable, Dispersible), 5 mg are white to off-white, round, flat- faced, radial-edged tablets with bisect on one side and plain on other side; one side of the bisect is debossed with "Z" and other side is debossed with "13" .  Lamotrigine Tablets (Chewable, Dispersible), 25 mg are white to off-white, round, flat- faced, radial-edged tablets debossed with logo of "Z" and "12" on one side and plain on the other side.		
<b>Odour</b>	Odourless	<b>Melting Point</b>	No Data Available
<b>Solubility in water</b>	No Data Available	<b>Vapour density</b>	No Data Available
<b>Boiling point</b>	No Data Available	<b>Evaporation rate</b>	No Data Available
<b>Evaporation rate</b>	No Data Available	<b>Specific gravity</b>	No Data Available
<b>Reactivity in water</b>	No Data Available	<b>Vapour pressure</b>	No Data Available
<b>% Volatile by volume</b>	No Data Available		
<b>Other information</b>	Lamotrigine is off-white to white crystalline powder and has a pKa of 5.7. Lamotrigine is soluble in dimethyl sulphoxide.		

### Section 9. Physical Hazards

<b>Condition to avoid</b>	Avoid exposure to extreme heat, light and moisture.	<b>Stable</b>	Stable under normal ambient and anticipated storage and handling conditions.
<b>Decomposition Products</b>	No Data Available	<b>Hazardous Reaction</b>	No data available.
<b>Incompatibilities</b>	No data available.		

### Section 10. Toxicological information

Handling of formulated product is not expected to cause any toxicological affects. The data pertains to the ingredient in formulations, rather than this specie formulation.

Target organ	Refer contraindication and adverse effect.
other	Not Available

# Material Safety data sheet

## LAMOTRIGINE TABLETS (CHEWABLE, DISPERSIBLE)

Strength: 2 mg.  
Strength: 5 mg and 25 mg

Pack Size: 90 and 100 Tablets per bottle  
Pack Size: 90,100 and 500 Tablets per bottle

Revision No.: 00

### Section 11. Ecological information

No data available on Ecotoxicity

### Section 12. Other information

None

**Date of issue:** 10/12/2008

**Supersedes edition of:** New Addition

The information contained herein is based on the state of our knowledge. It  
Characterises the product with regard to the appropriate safety precautions.  
It does not represent a guarantee of the properties of the product.